Comparing 18 vendors in Molecular Diagnostics across 0 criteria.

Market Presence
Contenders Contenders
Market Leaders Market Leaders
Emerging Companies Emerging Companies
Innovators Innovators
Qiagen
Revvity
Biocartis
BD
bioMérieux
Roche
Thermo Fisher
Hologic
Danaher
DiaSorin
Siemens Healthineers
Abbott
Illumina
Agilent
Grifols
QuidelOrtho
mdxhealth
Myriad Genetics
Product Footprint
copyright

Access Research To

  • Expand Total Addressable Market
  • Formulate Go To Market Plans
  • Build Competitive Right to Win
  • Identify Top Customers to Grow

Success!!!
You Already Have an Account! Please click here to signin
Error!!!
Oops! Something went wrong. Please try again later.
POWERED BY MARKETSANDMARKETS
Feb 24, 2024

The Molecular Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Molecular Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 80 companies of which the Top 18 Molecular Diagnostics Companies were categorized and recognized as the quadrant leaders.

Molecular diagnostics is a technique that identifies and analyzes nucleic acids or proteins at a molecular level. This technique assesses the genetic makeup of an individual to identify a predisposition to any particular disease or condition and diagnose it.

The 360 Quadrant maps the molecular diagnostics companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Molecular Diagnostics’ quadrant. While the top criteria for product footprint evaluation included Product (Reagents & Kits, Instruments, Services & Software), Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing & Next-generation Sequencing, DNA Microarrays, In Situ Hybridization, Other Technologies), Test Type (Lab Tests, PoC Tests), Application ((Infectious Disease Diagnostics (Hepatitis, HIV, CT/NG, HAI, HPV, Tuberculosis, Influenza, Other Infectious Diseases), Oncology Testing (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Other Cancers), Genetic Testing, COVID-19, Other Applications), Product Launches, Product Approvals, and R&D Expenditure.

Key trends highlighted in 360 Quadrant’s study include:

  • The estimated value of the Molecular Diagnostics market in 2023 is USD 15.6 billion, with a projected reach of USD 26.8 billion by 2028, reflecting a notable CAGR of 11.4% during the forecast period. The driving forces behind this market growth include the escalating prevalence of infectious diseases and cancer, coupled with increased funding for Research and Development (R&D) in the field of molecular diagnostics. Molecular Diagnostics companies are poised to play a crucial role in advancing these innovative technologies.
  • North America accounted for the largest share in the molecular diagnostics market, accounting for nearly 45%. The large share of North America in this market can be attributed to the increasing prevalence of infectious diseases and cancer, increasing healthcare spending, the highly developed healthcare system in the US and Canada. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America has several major molecular diagnostics companies in the molecular diagnostics sector.
  • During the forecast period, the Asia Pacific market is projected to experience the highest CAGR of 13.3%. This growth can be linked to several factors, including the escalating incidence of cancer, heightened governmental initiatives to enhance awareness of early disease detection, the increasing per capita income, the expansion of private-sector hospitals into rural regions across diverse Asia Pacific countries, and the existence of high-growth markets within the region. Furthermore, the region benefits from low labor costs and a favorable regulatory environment, factors that are anticipated to significantly contribute to the growth of the market. Molecular Diagnostics companies operating in the Asia Pacific region are well-positioned to capitalize on these conducive factors.
  • In 2022, the lab tests segment dominated the market, capturing a significant share of 87.6%. This is primarily due to the escalating demand for automation and the increasing prevalence of infectious diseases, attracting the attention of molecular diagnostics companies. The surge in chronic diseases, including cancer, underscores the necessity for diagnostic tests, making lab tests indispensable for disease detection, monitoring, and treatment decision-making. Further, the expanding prevalence of chronic conditions intensifies the demand for a diverse array of lab tests within the field of molecular diagnostics.
  • Based on applications, in 2022, the infectious disease diagnostics segment claimed the majority share, comprising 54.0% of the global molecular diagnostics market. This substantial share is credited to the advancement of sophisticated assays for diagnosing various diseases and conditions, the growing incidence of infectious diseases, and the increasing recognition of molecular diagnostics companies playing a pivotal role in effectively leveraging molecular diagnostic technologies/products to manage and curb the spread of infectious diseases.
  • In 2022, the PCR segment claimed the largest market share, accounting for nearly 42% of the molecular diagnostics market. This dominance is attributed to the increasing utilization of PCR in proteomics and genomics, the automation of PCR instruments, and the emergence of advanced technologies like qRT-PCR. Additionally, advancements in technologies such as next-generation sequencing (NGS), and microarray techniques, have expanded the capabilities of molecular diagnostics, enabling the detection of a wide range of genetic and infectious diseases.
  • The market for molecular diagnostics is highly competitive, with numerous companies offering a wide range of tests and platforms. Key molecular diagnostics companies in the industry include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific and Qiagen. These companies invest heavily in research and development to innovate and launch new products, aiming to improve sensitivity, specificity, and turnaround time of molecular diagnostic tests.
  • In a strategic move, leading molecular diagnostics companies like Thermo Fisher Scientific Inc. (US) and F. Hoffmann-La Roche Ltd. (Switzerland) have been driving industry advancements. Thermo Fisher strengthened its specialty diagnostics portfolio by acquiring Binding Site Group (UK) in February 2023, expanding capabilities for multiple myeloma diagnostics. In October 2022, Roche received FDA clearance for the cobas SARSCoV-2 Qualitative PCR test. Additionally, F. Hoffmann-La Roche collaborated with the Global Fund in May 2022 to enhance diagnostics infrastructure in low- and middle-income countries.

The Full List

The Full List

Company Headquarters Year Founded Holding Type
Abbott Chicago, USA 1888 Public
Agilent Santa Clara, USA 1999 Public
BD Franklin Lakes, USA 1897 Public
Biocartis Mechelen, Belgium 2007 Private
Danaher Washington, D.C., USA 1984 Public
DiaSorin Vercelli, Italy 1968 Private
Grifols Barcelona, Spain 1909 Public
Hologic Marlborough, USA 1985 Public
Illumina San Diego, USA 1998 Public
Myriad Genetics Salt Lake City , USA 1991 Public
Qiagen Hilden, Germany 1984 Public
QuidelOrtho San Diego, USA 1979 Public
Revvity Waltham, USA 2023 Public
Roche Basel, Switzerland 1896 Private
Siemens Healthineers Erlangen, Germany 1847 Public
Thermo Fisher Waltham, USA 1956 Private
bioMérieux AR, France 1963 Public
mdxhealth Herstal, Belgium 2003 Public
 
Frequently Asked Questions (FAQs)
The method of diagnosing an illness by studying molecules in a tissue or fluid such as proteins, DNA, and RNA.
A molecular test for a common inherited hereditary cancer can be performed by doctors. In the case of breast cancer, for example, they can look for specific hereditary abnormalities in the BRCA1 and BRCA2 genes that may increase the patient's chance of developing breast and ovarian cancer.
The Molecular Diagnostics Laboratory oversees developing and executing molecular diagnostic assays for nucleic acid targets present in a range of medical contexts.
Molecular diagnostics are increasingly being used to guide patient management, from diagnosis to treatment, in sectors such as cancer, infectious disease, and congenital anomalies.
These technologies are broadly classified as polymerase chain reaction (PCR), hybridization, and next-generation sequencing (NGS). Currently, the FDA has approved a large number of PCR and hybridization assays as in vitro diagnostics.
Molecular PCR testing. A polymerase chain reaction (PCR) test is a specific type of molecular test used to amplify specific sections of DNA for a wide range of purposes, such as: Other NAATs. Rapid molecular testing. Commercial at-home tests. Antibiotic susceptibility testing. Genetic tests.
In the future, molecular diagnostics may be able to guide clinicians to the best medicine for each patient, regardless of ailment. Despite the enormous promise of molecular diagnostics, laboratories that use it will undoubtedly encounter problems that are common to every new technology.
A single light-blue citrate tube is used to collect 3 mL of whole blood. The tubes are promptly sealed in plastic bags (at room temperature) and shipped to the Molecular Diagnostics Unit.
PCR is a chemical reaction that exponentially amplifies the targeted nucleic acid to detectable amounts, catalyzed by fast temperature cycling. The amount of genetic material in the beginning sample is doubled after one cycle of PCR. Performing numerous PCR cycles generates millions to billions of copies.
Protein methods, immunostaining methods, and nucleic acid methods are the most often utilized molecular biology methods.
 
Research Methodology
Research Methodology

360 Quadrants

360 Quadrants is a scientific research methodology by MarketsandMarkets to understand market leaders in 6000+ micro markets

360 Quadrants

360 Quadrants is a scientific research methodology by MarketsandMarkets to understand market leaders in 6000+ micro markets

Email : [email protected]

Quick Links